Skip to main content

Advertisement

SpringerLink
Log in

Sodium Iodide Symporter (NIS) in the Management of Patients with Thyroid Carcinoma

  • Perspective
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Although radioiodine has been applied in thyroid diseases including carcinoma for over 70 years, it was only in 1996 that the basic molecular mechanism of iodine uptake was identified. Iodide is actively transported into the thyroid via a membrane glycoprotein known as sodium iodide symporter (NIS). NIS mediates radioiodine uptake into thyroid normal and cancer cells. The knowledge on NIS expression has provided scientific background to the empirical management of thyroid carcinoma. Based on recent studies of the NIS gene, this paper provides current clinical applications and future studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fernandes JK, Day TA, Richardson MS, Sharma AK. Overview of the management of differentiated thyroid cancer. Curr Treat Options in Oncol. 2005;6:47–57.

    Article  Google Scholar 

  2. Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer. 2007;110:1451–6.

    Article  PubMed  Google Scholar 

  3. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid. 2009;19:1381–91.

    Article  CAS  PubMed  Google Scholar 

  4. Kim S, Chung JK, Min HS, Kang JH, Park DJ, Jeong JM, et al. Expression patterns of glucose transporter-1 gene and thyroid specific genes in human papillary thyroid carcinoma. Nucl Med Mol Imaging. 2014;48:91–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Chung JK, Cheon GJ. Radioiodine therapy in differentiated thyroid cancer: the first targeted therapy in oncology. Endocrinol Metabol. 2014;29(3):233–9.

    Article  Google Scholar 

  6. Lee J, Nah KY, Kim RM, Oh YJ, An YS, Yoon JK, et al. Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma. J Korean Med Sci. 2012;27:1019–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Fernandez CA, Puig-Domingo M, Lomena F, Estorch M, Camacho Marti V, Bittini AL, et al. Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake. J Endocrinol Investig. 2009;32:228–33.

    Article  CAS  Google Scholar 

  8. So YK, Son YI, Baek CH, Jeong HS, Chung MK, Ko YH. Expression of sodium-iodide symporter and TSH receptor in subclinical metastatic lymph nodes of papillary thyroid microcarcinoma. Ann Surg Oncol. 2012;19:990–5.

    Article  PubMed  Google Scholar 

  9. Chung JK, Kim MJ, Youn H. Lesionalized therapy beyond personalized therapy in cancer management. J Korean Med Sci. 2014;29(10):1331–2.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Min JJ, Chung JK, Lee Y, Jeong J, Lee D, Jang J, et al. Relationship between expression of the sodium/iodide symporter and (131) I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med. 2001;28:639–45.

    Article  CAS  PubMed  Google Scholar 

  11. Barbara S. Death but one unintended consequence of gene-therapy trial. CMAJ. 2001;164(11):1612.

    Google Scholar 

  12. Lee YJ, Chung JK, Kang JH, Jeong JM, Lee DS, Lee MC. Wild-type p53 enhances the cytotoxic effect of radionuclide gene therapy using sodium iodide symporter in a murine anaplastic thyroid cancer model. Eur J Nucl Med Mol Imaging. 2010;37(2):235–41.

    Article  CAS  PubMed  Google Scholar 

  13. Kim YH, Youn H, Na J, Hong KJ, Kang KW, Lee DS, et al. Codon-optimized human sodium iodide symporter (opt-hNIS) as a sensitive reporter and efficient therapeutic gene. Theranostics. 2015;5(1):86–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

I thank all my teachers, family members, and friends who gave me endless encouragement and support for the successful completion of this project.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea

    June-Key Chung, Hyun Woo Kim, Haewon Youn & Gi Jeong Cheon

Authors
  1. June-Key Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hyun Woo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haewon Youn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gi Jeong Cheon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hyun Woo Kim.

Ethics declarations

Conflict of Interest

June-Key Chung, Hyun Woo Kim, Haewon Youn, and Gi Jeong Cheon declare no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chung, JK., Kim, H.W., Youn, H. et al. Sodium Iodide Symporter (NIS) in the Management of Patients with Thyroid Carcinoma. Nucl Med Mol Imaging 52, 325–326 (2018). https://doi.org/10.1007/s13139-018-0540-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-018-0540-y

Keywords

Search

Navigation